Summary In order to judge the value of therapeutic regimens in paucibacillary leprosy, knowledge of incubation time of relapses is essential, as this will define the length of time patients have to be fo llowed up after treatment has been stopped. The prospective study of relapse includes paucibacillary cases of leprosy belonging to a non-lepromatous group consisting of tuberculoid, neuritic and indeterminate. Data are presented on the incubation time of 21 relapses after multidrug therapy in Baroda district; 76· 19% of relapses occur during the first 2 years. This figure is most important in the analysis of results of drug trials in paucibacillary leprosy. This figure should also be relevant to regimens including drugs that are more bacteriocidal than dapsone, since the bacteriocidal activity has a bearing on the minimal necessary duration of treatment, but not on the incubation time of relapses.
With the introduction of bactericidal drugs e.g. rifampicin in multidrug therapy, the incidence of relapse are very low, hence relapse rates fall down to a very low level after multidrug therapy. Our study shows a mean relapse rate of 0· 19% after multidrug therapy. Factors associated with the occurrence of relapse are discussed.
There have been only a few studies on relapse in non-lepromatous and intermediate groups of leprosy cases. The non-lepromatous cases fo rm the bulk of the case load of any leprosy control unit. It is recognized that with an effective treatment regimen these types of leprosy regress much more rapidly compared to the lepromatous type of leprosy. However, a certain amount of care has to be exercised while releasing them from control after inactivity to avoid relapses. 1,2 This study reports risk fa ctors contributing to relapses observed in the multidrug therapy project, Baroda district with the collaboration of the State Government, Government of India and World Health Organization.
Material and methods
The multidrug therapy project was started on II June 1984 and the intensive phase of 3 These cases of relapse were differentiated clinically from reversal reaction by slow and insidious onset, time interval of 6 months after stopping treatment, new lesions were minimal, lesion showed erythema and infiltration, ulceration does not occur and very slow response to treatment.
TREATMENT Paucibacillary cases were given dapsone 100 mg daily for 6 months and supervised rifampicin 600 mg once a month for 6 months.12 723 PB cases were clinically active, erythema and infiltration were still persisting. Therefore a fu rther extension of treatment for 6 months were given to 723 cases. All PB cases released from treatment were fo llowed once in 6 months for 2 years.
Results/Observations (Non-lepromatous and paucibacillary used synonymously; RR = Relapse rate)
The observations are given in the tables. Table I) It will be observed fr om Table I , which gives the number of relapse cases over the years, that the relapse rate has been rising which is natural as the number of cases discharged have been increasing cumulatively. The average relapse rate is 0· 19%. All 21 relapsed cases were on multidrug therapy and all cases were also bacteriologically positive. Table I shows the number of cases that relapsed yearly out of the total number of PB cases released from treatment. The first case relapsed in the year 1984-85 out of 12 IO PB cases released from treatment. Thus 21 cases relapsed out of the 10,995 PB cases released from treatment with a mean relapse rate of 0· 19%. Relapses in leprosy are less common after giving multidrug therapy compared to relapses after dapsone monotherapy. Our study shows a very low 0· 19% relapse rate after multidrug therapy. (Table 2) The proportion of males to fe males is more in relapse cases. In fa ct, the usual male preponderance in the disease prevalence is exaggerated in the relapse cases. Amongst both males and fe males the higher age groups faced more relapse, especially in the 20-30 and over 40 age groups. Out of 21 relapsed cases only 6 cases were irregular in treatment (28'5%) as shown in Table 2 .
RELAPSE RATE: (

AGE AND SEX IN RELAPSE CASES:
CHANGE TN TYPE: (Table 3) In connection with classification of leprosy in the field it was noticed that patients had been classified as tuberculoid even when there were multiple lesions. Many of these cases would be classified as borderline tuberculoid at the present time. If the modern concept of classification had been applied perhaps cases would not have been released without a longer maintenance treatment. It will be observed that only 4 (23'80%) out of 17 PB originally termed T have been relapsed to T but the remaining 13 have relapsed by changing their types. It can be seen from Table 3 on the number of patches that there were cases without skin lesions who were either primary polyneuritic or secondary polyneuritic or had infiltration. It will be observed that these cases have been transformed into more serious fo rms. In our study of relapse 2 cases were pure neuritic type without any evidence of a history of skin lesions whereas one case was of secondary polyneuritic in which multiple nerves were thickened and tender with a past history of skin lesions. (Table 4) Out of 21 relapsed cases, 17 cases had no deformities and 4 cases developed deformity on relapse, out of which two had grade 2, one had grade I and one had grade 3 deformity. 15 cases were regular in treatment and the remaining 6 cases were irregular out of which two developed grade 2 deformity and one developed grade 3 deformity.
DEFORMITY STATUS AND RELAPSE:
The above table shows time of relapses (release interval) in PB cases after MDT. The majority of relapsed cases in our study after treatment manifest themselves within a period of 3 years , Out of 21 relapses 16 relapses (76, 19%) manifested within 2 years of the completion of multi drug therapy and the remaining 5 cases (23,80%) relapsed in the 3rd year.
Discussion .
In the early days of sulphone therapy Lowe had observed 11· 6% of relapse which had occurred in 6-12 months after stopping treatment.6 Davey3 had reported a relapse rate of 6% in tuberculoid cases, among indeterminate and borderline cases the relapse rate was 29%. Ekambaram4 had reported a relapse rate of 1·8% in patients treated for 5-6 years with 56% occurring within the first 2 years and 73·5% within the first 3 years. Ramu & Ramanujam8 fo und a relapse rate of 4-4% in borderline cases treated for 3-9 years after subsidence and no relapses were seen after the 5th year. Girdhar et al. 5 fo und a relapse rate of 2· 5% in patients treated according to conventional methods of induction, relapses in leprosy are common after dapsone monotherapy. Repeated relapses in single cases have not been documented though there may be a few such instances. Vellutll fo und that longer maintenance fo llow-up led to a lower risk of relapse. Relapses after giving multidrugs are expected to be less common compared to relapses after dapsone monotherapy. The present study proves relapses are less common in multidrug therapy, in comparison to the above studies on dapsone monotherapy; out of 21 relapses 16 manifested in the first 2 years (76' 19%) and the remaining 5 cases (23'80%) relapsed in the 3rd year. Touw-Langendijk & Naafslo observed a 14% relapse among T.T. patients treated for 1·5 years and 28% for patients treated less than 5 years. Differences in these studies may be the result of differences in the fo llow-up period or different diagnostic criteria between clinicians. In our study each relapse case was documented by histopathology. It may be that some relapses appearing early after stopping treatment, for instance during the first year, may in reality be upgrading reaction. Where onset is sudden, new lesions are maximum and these lesions may ulcerate, multiple nerve involvement with pain and tenderness and respond to antireactional treatment rapidly. It is frequently argued that the nature of drugs, for example RFM instead of dapsone, will profoundly influence the incubation time for relapses. This results from confusion of two different issues: the incidence of reJapses and the moment at which they appear. Indeed, nature and duration of therapy must influence the incidence of relapses, since these are the result of insufficient killing of aetiologic bacilli. However, the moment at which the survivors start to multiply again in most patients must be independent of the kind of anti-bacterial treatment administered. Survivors are survivors, whether the dead ones were killed by dapsone or rifampicin or any other drug.
Relapse is the result of bacterial multiplication starting anew from the survivors remaining after insufficient chemotherapy, due to an insufficiently bacteriocidal drug or to a therapeutic regimen that was too short. It should be mentioned that shortcomings of bacteriocidal activity of drugs is frequently corrected by prolonging the duration of chemotherapy.
In conclusion relapses in leprosy are common after dapsone monotherapy. Relapses after giving multidrugs are expected to be less common compared to relapses after dapsone monotherapy. Our study shows a very low 0· 19% relapse rate after multidrug therapy. The majority of relapsed cases in our study after treatment manifest themselves within a period of 3 years. Out of 21 relapses, 16 relapses (76, 19%) manifested within the first 2 years of completion of muItidrug therapy and the remaining 5 cases (23'80%) relapsed in the 3rd year. With the introduction of bacteriocidal drugs, e.g. rifampicin, in multidrug therapy, the incidence of relapse are very low, hence relapse rates fa ll down to a very low level after multidrug therapy. Our study shows a mean relapse rate of 0· 19% after muItidrug therapy.
